Abivax (AAVXF) Change in Account Payables (2024 - 2026)

Abivax has reported Change in Account Payables for 3 years, with the latest figure at -$9.4 million in Q1 2026.

• On a quarterly basis, Change in Account Payables fell 170.23% year-over-year to -$9.4 million in Q1 2026; TTM through Mar 2026 was -$7.3 billion, a 97.52% decrease from a year earlier, with the FY2025 full-year figure at -$7.2 billion, down 96.42% from the prior year.
• Change in Account Payables was -$9.4 million for Q1 2026 at Abivax, up from -$7.2 billion in the prior quarter.
• The five-year high for Change in Account Payables was $15.0 million in Q3 2024, with the low at -$7.2 billion in Q4 2025.
• Average Change in Account Payables over 3 years is -$1.2 billion, with a median of -$9.4 million recorded in 2026.
• The largest YoY upside for Change in Account Payables was 137.53% in 2025 against a maximum downside of 318.09% in 2025.
• Over 3 years, Change in Account Payables stood at -$3.7 billion in 2024, then tumbled by 96.17% to -$7.2 billion in 2025, then soared by 99.87% to -$9.4 million in 2026.
• The last three Change in Account Payables figures came in at -$9.4 million (Q1 2026), -$7.2 billion (Q4 2025), and -$32.7 million (Q3 2025), per Business Quant data.